This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Quotient Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Quotient.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	16.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Quotient expands MosaiQ Innovator's Circle

Aug 24

Quotient teams up with InfYnity Biomarkers to advance infectious disease testing

Jul 12

Analysts Just Shaved Their Quotient Limited (NASDAQ:QTNT) Forecasts Dramatically

Feb 10

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Quotient has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:QTNT.Q - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2022	37	-124	-114	-112	N/A
9/30/2022	38	-156	-127	-125	N/A
6/30/2022	38	-137	-125	-123	N/A
3/31/2022	39	-125	-122	-119	N/A
12/31/2021	38	-139	-120	-117	N/A
9/30/2021	37	-125	-110	-106	N/A
6/30/2021	44	-113	-90	-85	N/A
3/31/2021	43	-111	-82	-78	N/A
12/31/2020	42	-96	-77	-73	N/A
9/30/2020	42	-92	-73	-69	N/A
6/30/2020	33	-105	-85	-80	N/A
3/31/2020	33	-103	-85	-81	N/A
12/31/2019	32	-105	-85	-79	N/A
9/30/2019	31	-103	-83	-77	N/A
6/30/2019	29	-104	-84	-80	N/A
3/31/2019	29	-105	-80	-76	N/A
12/31/2018	27	-99	-84	-77	N/A
9/30/2018	26	-93	-88	-77	N/A
6/30/2018	26	-87	-88	-70	N/A
3/31/2018	25	-82	-90	-68	N/A
12/31/2017	24	-83	-89	-66	N/A
9/30/2017	23	-93	-83	-60	N/A
6/30/2017	23	-89	-81	-62	N/A
3/31/2017	22	-85	-76	-56	N/A
12/31/2016	22	-74	-71	-47	N/A
9/30/2016	21	-53	N/A	-49	N/A
6/30/2016	19	-40	N/A	-49	N/A
3/31/2016	19	-34	N/A	-47	N/A
12/31/2015	17	-27	N/A	-51	N/A
9/30/2015	17	-59	N/A	-40	N/A
6/30/2015	17	-67	N/A	-33	N/A
3/31/2015	18	-59	N/A	-27	N/A
12/31/2014	19	-62	N/A	-18	N/A
9/30/2014	19	-23	N/A	-15	N/A
6/30/2014	19	-13	N/A	-7	N/A
3/31/2014	20	-10	N/A	-4	N/A
12/31/2013	19	-7	N/A	-6	N/A
9/30/2013	18	-5	N/A	-5	N/A
6/30/2013	17	-3	N/A	-6	N/A
3/31/2013	14	-5	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if QTNT.Q's forecast earnings growth is above the savings rate (2.1%).

Earnings vs Market: Insufficient data to determine if QTNT.Q's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if QTNT.Q's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if QTNT.Q's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if QTNT.Q's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if QTNT.Q's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company listing is no longer active

Quotient Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased to US$90.00

Consensus EPS estimates fall by 25%

Quotient Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023

Consensus estimates of losses per share improve by 40%

Price target decreased to US$2.75

Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023

Recent updates

Quotient Limited Filed for Bankruptcy

Quotient Limited(OTCPK:QTNT.F) dropped from NASDAQ Composite Index

Quotient Limited Announces Resignation of Franz Walt as Director

Quotient Announces Intent to Voluntary Delist from the Nasdaq Global Market

Price target increased to US$90.00

High number of new directors

Quotient Limited Announces the Retirement of Brian McDonough as Member of the Board of Directors

High number of new directors

High number of new directors

Independent Chairman of the Board recently bought US$140k worth of stock

Quotient Limited Appoints Sophie Bechu as A Director

Quotient expands MosaiQ Innovator's Circle

Consensus EPS estimates fall by 25%

Quotient Receives Non-Compliance Letter from Nasdaq

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Quotient Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023

Quotient Limited to Report Q1, 2023 Results on Aug 09, 2022

Quotient Limited, Annual General Meeting, Oct 31, 2022

Quotient Limited Announces Executive Changes

Quotient teams up with InfYnity Biomarkers to advance infectious disease testing

Consensus estimates of losses per share improve by 40%

Price target decreased to US$2.75

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023

Quotient Limited to Report Q4, 2022 Results on Jun 22, 2022

Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Limited Appoints Thomas Aebischer to Quotient Board of Directors, Effective as of May 1, 2022

Quotient Limited Appoints Manuel O. Méndez as Director

Price target increased to US$7.67

Quotient Limited Appoints Thomas Aebischer to Board of Directors, Effective as of May 1, 2022

Independent Chairman of the Board recently bought US$78k worth of stock

Price target decreased to US$7.75

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analysts Just Shaved Their Quotient Limited (NASDAQ:QTNT) Forecasts Dramatically

Consensus forecasts updated

Quotient Limited to Report Q3, 2022 Results on Feb 08, 2022

Chief Commercial Officer recently bought US$103k worth of stock

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 2Q 2021)

Chief Commercial Officer Jeremy Stackawitz has left the company

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.32 loss in 1Q 2021)

Price target decreased to US$10.50

Full year 2021 earnings released: US$1.18 loss per share (vs US$1.44 loss in FY 2020)

Quotient Limited Provides Revenue Guidance for the First Quarter and Full Year Ending March 31, 2022

Quotient beats on revenue; issues guidance

Quotient Limited announced that it has received $95 million in funding from Highbridge Capital Management, LLC, CI Global Asset Management, Russell Investments Canada Ltd., Whitebox Advisors, LLC

Chief Operating Officer notifies of intention to sell stock

Quotient Limited announced that it expects to receive $95 million in funding from Highbridge Capital Management, LLC and other investors

Here's Why Quotient (NASDAQ:QTNT) Can Afford Some Debt

A Look At Quotient's (NASDAQ:QTNT) Share Price Returns

Quotient Limited Announces Manuel Mendez as Chief Executive Officer, Effective April 1, 2021

New 90-day low: US$4.92

Chief Operating Officer exercised options and sold US$487k worth of stock

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.37 loss in 3Q 2020)

Revenue beats expectations, earnings disappoint

New 90-day low: US$5.04

Quotient EPS beats by $0.01, beats on revenue

Read This Before Selling Quotient Limited (NASDAQ:QTNT) Shares

Quotient Limited to Report Q3, 2021 Results on Feb 01, 2021

Is Quotient (NASDAQ:QTNT) A Risky Investment?

Quotient Limited Announces Resignation of Ed Farrell from His Position as Chief Operating Officer

Quotient operations chief resigns

New 90-day high: US$7.32

Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market

Quotient drops ~7% as FDA requires additional data for regulatory clearance

Quotient (NASDAQ:QTNT) Shareholders Have Enjoyed A 58% Share Price Gain

New 90-day high: US$6.15